Literature DB >> 23945031

The clinical evaluation of International Normalized Ratio variability and control in conventional oral anticoagulant administration by use of the variance growth rate.

S Ibrahim1, J Jespersen, L Poller.   

Abstract

INTRODUCTION: The time in target International Normalized Ratio (INR) range (TIR) is used to assess the control and intensity of oral anticoagulation, but it does not measure variation in the INR.
OBJECTIVES: The value of assessing INR variability by use of the variance growth rate (VGR) as a predictor of events was investigated in patients treated with warfarin.
METHODS: Three different methods of VGR determination (A, B1, and B2) together with the TIR were studied. Method A measures both INR variability and control, but methods B1 and B2 measure variability only. The VGR and TIR were determined over three time periods: overall follow-up to an event, and 6 months and 3 months before an event.
RESULTS: Six hundred and sixty-one control patients were matched to 158 cases (bleeding, thromboembolism, or death). With all VGR methods, the risk of an event was greater in unstable patients at 6 months before an event than in stable patients. Method A demonstrated the greatest risk 3 months before an event in the unstable VGR group as compared with the stable group (odds ratio 3.3, 95% confidence interval 1.9-5.7, P < 0.005). The risk of an event was 1.9 times greater in patients with a low TIR (< 39%) than in those with a high TIR (> 80%) in the 3-month period (P = 0.02). Risk of bleeding was significantly greater in the 3-month period in patients with unstable VGR, with the greatest risk found with method B2 (P < 0.01).
CONCLUSIONS: Patients with unstable anticoagulation have a significantly increased risk of 'clinical events' at 3 and 6 months before an event. The VGR can be incorporated into computer-dosage programs, and may offer additional safety when oral anticoagulation is monitored.
© 2013 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  International Normalized Ratio; Marevan; analysis of variance; antithrombotic agents; warfarin

Mesh:

Substances:

Year:  2013        PMID: 23945031     DOI: 10.1111/jth.12322

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  6 in total

1.  Reduced anticoagulation variability in patients on warfarin monitored with Fiix-prothrombin time associates with reduced thromboembolism: The Fiix-trial.

Authors:  Alma Rut Oskarsdóttir; Brynja R Gudmundsdottir; Olafur S Indridason; Sigrun H Lund; David O Arnar; Einar S Bjornsson; Magnus K Magnusson; Hulda M Jensdottir; Brynjar Vidarsson; Charles W Francis; Pall T Onundarson
Journal:  J Thromb Thrombolysis       Date:  2017-05       Impact factor: 2.300

Review 2.  Engaging with quality improvement in anticoagulation management.

Authors:  Geoffrey D Barnes; Eva Kline-Rogers
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

3.  Ignoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study.

Authors:  Alma R Oskarsdottir; Brynja R Gudmundsdottir; Hulda M Jensdottir; Bjorn Flygenring; Ragnar Palsson; Pall T Onundarson
Journal:  Blood       Date:  2021-05-20       Impact factor: 22.113

Review 4.  Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.

Authors:  Jonathan Douxfils; Anne Tamigniau; Bernard Chatelain; Catherine Goffinet; Jean-Michel Dogné; François Mullier
Journal:  Thromb J       Date:  2014-11-04

5.  Clinical Outcomes of Telemonitoring for Patients on Warfarin after Discharge from Hospital.

Authors:  Natthaporn Sudas Na Ayutthaya; Itsarawan Sakunrak; Teerapon Dhippayom
Journal:  Int J Telemed Appl       Date:  2018-08-12

6.  Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease.

Authors:  Judith Kooiman; Nienke van Rein; Bas Spaans; Koen A J van Beers; Jonna R Bank; Wilke R van de Peppel; Antonio Iglesias del Sol; Suzanne C Cannegieter; Ton J Rabelink; Gregory Y H Lip; Frederikus A Klok; Menno V Huisman
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.